The application of theranostics in different stages of prostate cancer
- Author(s)
- Alghazo, O; Eapen, R; Koschel, S; Cumberbatch, M; Buteau, J; Loh, R; Lawrentschuk, N; Murphy, DG;
- Details
- Publication Year 2021-09,Volume 17,Issue #27,Page 3637-3644
- Journal Title
- Future Oncology
- Publication Type
- Review
- Abstract
- Despite the remarkable achievements in treating metastatic prostate cancer over the last two decades, castrate-resistant status is still considered the lethal stage of the disease. Theranostics combines a targeting compound (ligand) with a therapeutic radioisotope (radioactive particle) injected into the blood to target the cancer cells. The most studied radioligand is (177)Lu-PSMA-617, which targets PSMA, a protein found in prostate cancer cells. This new approach has shown promising results in treating metastatic castration-resistant prostate cancer. Currently, many trials are using PSMA-targeting radioligands in combination with conventional therapies in advanced prostate cancer or even in the earlier stages of the disease. Other preclinical trials are exploring the possibility of using newer ligands or radioisotopes to treat prostate cancer to increase the specificity and efficacy of this treatment.
- Keywords
- Clinical Trials as Topic; Humans; Lutetium/therapeutic use; Male; Neoplasm Staging; *Precision Medicine/trends; Prostate-Specific Antigen/therapeutic use; Prostatic Neoplasms/pathology/*radiotherapy; Radiopharmaceuticals/therapeutic use; Radiotherapy/methods; 177Lu-PSMA-617; LuPSMA; Psma; targeted radionuclide therapy; theranostics in prostate cancer
- Department(s)
- Cancer Imaging; Surgical Oncology
- PubMed ID
- 34227404
- Publisher's Version
- https://doi.org/10.2217/fon-2020-1209
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-05-23 04:02:50
Last Modified: 2025-05-23 04:04:10